Prof John Zajicek

Prof John Zajicek
Chair in Medicine

data source: symbiosis

Research Overview from research@st-andrews

Professor John Zajicek trained in Medicine at Cambridge and St Mary’s Hospital in London. He completed a PhD in cell biology in Cambridge, moved to Plymouth in 1995 as a Consultant Neurologist, and took up the Chair of Clinical Neuroscience at Plymouth University. In Plymouth he was Director of the Peninsula Clinical Trials Unit, and Chair of the UK NIHR Nervous System Disorders Specialty Group. He has recently moved to the University of St Andrews, where he is Professor of Medicine. Zajicek has served on the UK MRC Neuroscience and Mental Health Board and the MRC Methodology Panel. He is particularly interested in the way we do trials for neurodegenerative diseases, has been Chief Investigator in several large multicentre randomized controlled trials, including the investigation of cannabinoid use to slow neurodegeneration. He has authored many papers on cannabinoids, multiple sclerosis and the methodology of clinical trials in neurodegeneration, including Alzheimer’s and Parkinson’s diseases.

Recent publications listed in research@st-andrews
25 (of 97 published available) for jz45 (source: University of St Andrews PURE)
Please click title of any item for full details

Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS) Jennifer A Freeman, Wendy Hendrie, Louise Jarrett, Annie Hawton, Andrew Barton, Rachel Dennett, Benjamin Jones, John Peter Zajicek, Siobhan Creanor
Lancet Neurology 2019 vol.18 pp.736-747
Improving the quality of cognitive screening assessments C. G. . Newman, A. Bevins, John Peter Zajicek, J. Hodges, E. Vuillermoz, J. Dickenson, D. Kelly, S. Brown, R. Noad
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2018 vol.10 pp.182-187
Machine-learning based identification of undiagnosed dementia in primary care Emmanuel A. Jammeh, Camille B. Carroll, Stephen W. Pearson, Javier Escudero, Athanasios Anastasiou, Peng Zhao, Todd Chenore, John Peter Zajicek, Emmanuel Ifeachor
BJGP Open 2018 vol.2 
Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis H. Gunn, J. Andrade, L. Paul, L. Miller, S. Creanor, C. Green, J. Marsden, P. Ewings, M. Berrow, J Vickery, A. Barton, B. Marshall, John Peter Zajicek, J. A. Freeman
Pilot and Feasibility Studies 2017 vol.4 
A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease David J. M. McGhee, Craig W. Ritchie, John Peter Zajicek, Carl E. Counsell
BMC Neurology 2016 vol.16 pp.1-13
Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis Marie-Louise Zeissler, Jordan Eastwood, Kieran McCorry, C. Oliver Hanemann, John Peter Zajicek, Camille B Carroll
Oncotarget 2016 vol.7 pp.46603-46614
Long-term safety and efficacy of teriflunomide Paul O'Connor, Giancarlo Comi, Mark S Freedman, Aaron E Miller, Ludwig Kappos, Jean-Pierre Bouchard, Christine Lebrun-Frenay, Jan Mares, Myriam Benamor, Karthinathan Thangavelu, Jinjun Liang, Philippe Truffinet, Victoria J Lawson, Jerry S Wolinsky, John Peter Zajicek
Neurology 2016 vol.86 pp.920-930
Standing up in multiple sclerosis (SUMS) J. A. Freeman, W. Hendrie, S. Creanor, L. Jarrett, A. Barton, C. Green, J. Marsden, E. Rogers, John Peter Zajicek
BMC Neurology 2016 vol.16 pp.1-10
Time-and region-specific season of birth effects in multiple sclerosis in the United Kingdom Pedro María Rodríguez Cruz, Lucy Matthews, Mike Boggild, Ana Cavey, Cris S. Constantinescu, Nikos Evangelou, Gavin Giovannoni, Orla Gray, Stanley Hawkins, Richard Nicholas, Maylin Oppenheimer, Neil Robertson, John Peter Zajicek, Peter M. Rothwell, Jacqueline Palace
JAMA Neurology 2016 vol.73 pp.954-960
Association of British Neurologists Neil Scolding, David Barnes, Sarah Cader, Jeremy Chataway, Abhijit Chaudhuri, Alasdair Coles, Gavin Giovannoni, David Miller, Waqar Rashid, Klaus Schmierer, Abdullah Shehu, Eli Silber, Carolyn Young, John Peter Zajicek
Practical Neurology 2015 vol.15 pp.273-279
Lending a hand Louise Barrett, Stefan Cano, John Peter Zajicek, Jeremy Hobart
Multiple Sclerosis Journal 2015 vol.21 pp.612-621
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial Susan Ball, Jane Vickery, Jeremy Hobart, Dave Wright, Colin Green, James Shearer, Andrew Nunn, Mayam Gomez Cano, David MacManus, David Miller, Shahrukh Mallik, John Peter Zajicek
Health Technology Assessment 2015 vol.19 pp.vii-viii, xxv-xxxi, 1-187
Using 'dead or dependent' as an outcome measure in clinical trials in Parkinson's disease David McGhee, Alexander Parker, Shona Fielding, John Peter Zajicek, Carl Counsell
Journal of Neurology, Neurosurgery, and Psychiatry 2015 vol.86 pp.180-185
A systematic review of biomarkers for disease progression in Alzheimer's disease David J M McGhee, Craig W Ritchie, Paul A Thompson, David E Wright, John Peter Zajicek, Carl E Counsell
PLoS One 2014 vol.9 
Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson's disease David Hilton, Madeleine Stephens, Leanne Kirk, Philip Edwards, Ross Potter, John Peter Zajicek, Ellie Broughton, Hannah Hagan, Camille Carroll
Acta Neuropathologica 2014 vol.127 pp.235-41
Pharmacology Richard Hosking, John Peter Zajicek
Practical Neurology 2014 vol.10 pp.429-30
A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis Rosella Mechelli, Renato Umeton, Claudia Policano, Viviana Annibali, Giulia Coarelli, Vito A G Ricigliano, Danila Vittori, Arianna Fornasiero, Maria Chiara Buscarinu, John Peter Zajicek, Silvia Romano, Marco Salvetti, Giovanni Ristori
PLoS One 2013 vol.8 
A systematic review of biomarkers for disease progression in Parkinson's disease David J M McGhee, Pamela L Royle, Paul A Thompson, David E Wright, John Peter Zajicek, Carl E Counsell
BMC Neurology 2013 vol.13 
Achieving valid patient-reported outcomes measurement Jeremy Hobart, Stefan Cano, Rachel Baron, Alan Thompson, Steven Schwid, John Peter Zajicek, David Andrich
Multiple Sclerosis Journal 2013 vol.19 pp.1773-83
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis Ashley H Beecham, Nikolaos A Patsopoulos, Dionysia K Xifara, Mary F Davis, Anu Kemppinen, Chris Cotsapas, Tejas S Shah, Chris Spencer, David Booth, An Goris, Annette Oturai, Janna Saarela, Bertrand Fontaine, Bernhard Hemmer, Claes Martin, Frauke Zipp, Sandra D'Alfonso, Filippo Martinelli-Boneschi, Bruce Taylor, Hanne F Harbo, Ingrid Kockum, Jan Hillert, Tomas Olsson, Maria Ban, Jorge R Oksenberg, Rogier Hintzen, Lisa F Barcellos, Cristina Agliardi, Lars Alfredsson, Mehdi Alizadeh, Carl Anderson, Robert Andrews, Helle Bach Søndergaard, Amie Baker, Gavin Band, Sergio E Baranzini, Nadia Barizzone, Jeffrey Barrett, Céline Bellenguez, Laura Bergamaschi, Luisa Bernardinelli, Achim Berthele, Viola Biberacher, Thomas M C Binder, Hannah Blackburn, Izaura L Bomfim, Paola Brambilla, Simon Broadley, Bruno Brochet, John Peter Zajicek,
Nature Genetics 2013 vol.45 pp.1353-60
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID) John Peter Zajicek, Susan Ball, David Wright, Jane Vickery, Andrew Nunn, David Miller, Mayam Gomez Cano, David McManus, Sharukh Mallik, Jeremy Hobart,
Lancet Neurology 2013 vol.12 pp.857-65
Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors Holly B Posner, Stefan Cano, Maria C Carrillo, Ola Selnes, Yaakov Stern, Ronald G Thomas, John Peter Zajicek, Jeremy Hobart,
Alzheimer's and Dementia 2013 vol.9 pp.S56-60
Evaluating change in mobility in people with multiple sclerosis Jennifer Freeman, Richard Walters, Wendy Ingram, Anita Slade, Jeremy Hobart, John Peter Zajicek
Multiple Sclerosis Journal 2013 vol.19 pp.1632-9